METHOD FOR INDUCING DIFFERENTIATION OF INTERMEDIATE MESODERMAL CELL TO RENAL PROGENITOR CELL AND METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELL TO RENAL PROGENITOR CELL

• Main Authors: OSAFUNE KENJI, KASAHARA TOMOKO, SUETA SHINICHI
• Format: Patent
• Language: English; Korean
• Published: 30.10.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, ORSURGICAL ARTICLES; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICALARTICLES; MEDICAL OR VETERINARY SCIENCE; METALLURGY; METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS INGENERAL; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

본 발명은 다능성 줄기세포로부터 신장 전구 세포를 제조하는 방법으로서, 다음의 공정 (i) ~ (vi)을 포함하는 방법이다. (i) 다능성 줄기세포를 FGF2, BMP4, GSK-3β 억제제 및 레티노산 또는 그 유도체를 포함하는 배지에서 배양하는 공정; (ii) 공정 (i)에서 얻어진 세포를 FGF2, GSK-3β 억제제 및 BMP7을 포함하는 배지에서 배양하는 공정; (iii) 공정 (ii)에서 얻어진 세포를 FGF2, GSK-3β 억제제, BMP7 및 TGFβ 억제제를 포함하는 배지에서 배양하는 공정; (iv) 공정 (iii)에서 얻어진 세포를 FGF2, GSK-3β 억제제, BMP7, 액티빈 및 ROCK(Rho-kinase) 억제제를 포함하는 배지에서 배양하는 공정; (v) 공정 (iv)에서 얻어진 세포를 레티노산 또는 그 유도체 및 FGF9를 포함하는 배지에서 배양하는 공정; 및 (vi) 공정 (v)에서 얻어진 세포를 GSK-3β 억제제 및 FGF9를 포함하는 배지에서 배양하고, 중간 중배엽 세포로부터 신장 전구 세포를 유도하는 공정. A method of producing renal progenitor cells from pluripotent stem cells, the method including the following Steps (i) to (vi): (i) a step of culturing pluripotent stem cells in a medium containing FGF2, BMP4, a GSK-3β inhibitor, and retinoic acid or a derivative thereof; (ii) a step of culturing cells obtained in Step (i) in a medium containing FGF2, a GSK-3β inhibitor, and BMP7; (iii) a step of culturing cells obtained in Step (ii) in a medium containing FGF2, a GSK-3β inhibitor, BMP7, and a TGFβ inhibitor; (iv) a step of culturing cells obtained in Step (iii) in a medium containing FGF2, a GSK-3β inhibitor, BMP7, activin, and a ROCK (Rho-kinase) inhibitor; (v) a step of culturing cells obtained in Step (iv) in a medium containing retinoic acid or a derivative thereof, and FGF9; and (vi) a step of culturing cells obtained in Step (v) in a medium containing a GSK-3β inhibitor and FGF9, to induce renal progenitor cells from intermediate mesodermal cells.